ORIC Pharmaceuticals, Inc. (ORIC)

ORIC Pharmaceuticals is a clinical-stage biotech advancing a differentiated oncology pipeline, anchored by lead assets targeting resistance mechanisms in cancer — a high-value niche that has drawn near-unanimous analyst buy ratings from 15 covering analysts. The consensus price target of $21.00 implies ~51% upside from current levels, reflecting significant optionality in upcoming clinical readouts. The primary risk is binary trial outcomes: as a pre-revenue, loss-making company, pipeline failures could materially impair the stock with no earnings floor to provide support.

• Upcoming clinical data readouts from lead oncology pipeline candidates, where positive Phase 1/2 results could serve as major re-rating events.
• Potential partnership or licensing deals with larger pharma players attracted to ORIC's resistance-mechanism platform, unlocking non-dilutive capital.
• Expansion of analyst coverage or institutional ownership following pipeline milestones, which could drive multiple expansion toward the $21.00 consensus target.

• Binary clinical trial risk: failure of any lead asset in upcoming readouts could erase a significant portion of market cap with no earnings buffer.
• Cash burn and dilution risk: as a pre-revenue biotech, ORIC will likely require additional equity financing, potentially diluting existing shareholders.
• Competitive landscape risk: large oncology pipelines from well-capitalized pharma companies could render ORIC's resistance-focused assets less differentiated or commercially viable.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →